Senator Marco Rubio (R-FL) sent a letter to FDA Commissioner Robert Califf and DHS Secretary Alejandro Mayorkas demanding they guarantee that goods imported to the United States are not made with slave labor.
In 2021, Rubio introduced the Uyghur Forced Labor Prevention Act (UFLPA), which was signed into law. The Act would “ensure that goods made with the slave labor of Uyghurs and other predominantly Muslim ethnic groups in the Xinjiang Uyghur Autonomous Region and elsewhere in the People’s Republic of China do not enter the United States,” Rubio’s website noted.
In the letter, Rubio noted “recent reports identifying two pharmaceutical producers based in the Xinjiang Uyghur Autonomous Region (XUAR) of the People’s Republic of China (PRC) that are permitted by the U.S. Food and Drug Administration (FDA) to distribute their products in the U.S.,” adding, “This is in clear violation of current law which prohibits imports from the region due to the Chinese Communist Party’s (CCP) egregious human rights abuses, including genocide, forced abortions, and forced sterilizations.”
MATT WALSH’S ‘AM I RACIST?’ NOW STREAMING ON DAILYWIRE+
“Recent analysis by the Centers for Advanced Defense Studies exposed that the FDA currently allows at least two pharmaceutical producers, Xinjiang Nuziline Bio-Pharmaceutical Co. and SEL Biochem Xinjiang Co. to import APIs and drug products into the U.S.,” Rubio continued. “Both of these companies are linked to slave labor in Xinjiang and are not listed on the UFLPA Entity List.”
“The Uyghur Forced Labor Prevention Act assures the American people that the products they purchase were made without slave labor,” Rubio wrote. “It is clear that the lack of oversight by the FDA has not made this true. The FDA and DHS have a responsibility to rectify this dangerous error and uphold the law. Therefore, I demand both departments and the Forced Labor Enforcement Task Force to immediately place Xinjiang Nuziline Bio-Pharmaceutical Co. and SEL Biochem Xinjiang Co. on the UFLPA Entity List. I also ask that the FDA and DHS complete a thorough review of every company authorized to distribute pharmaceuticals and API in the United States to ensure compliance with the Uyghur Forced Labor Prevention Act.”
